載入...
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
Alemtuzumab is a humanized monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS), given as two annual courses on five consecutive days at baseline and on three consecutive days 12 months later. Here we provide an update on the long-term efficacy and safety o...
Na minha lista:
| 發表在: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5607928/ https://ncbi.nlm.nih.gov/pubmed/28966663 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285617722706 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|